Prophylactic cranial irradiation in small cell lung cancer: A review of evidence

Fundings

None.

Acknowledgments

None.

References

[1] Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung cancer[J]. Nat Rev Dis Primers, 2021, 7(1): 3. doi: 10.1038/s41572-020-00235-0

[2] Ganti AKP, Loo BW, Bassetti M, et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(12): 1441-1464. doi: 10.6004/jnccn.2021.0058

[3] Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission[J]. N Engl J Med, 1999, 341(7): 476-484. doi: 10.1056/NEJM199908123410703

[4] Nugent JL, Bunn PA Jr, Matthews MJ, et al. CNS metastases in small cell bronchogenic carcinoma. Increasing frequency and changing pattern with lengthening survival[J]. Cancer, 1979, 44(5): 1885-1893. doi: 10.1002/1097-0142(197911)44:5<1885::AID-CNCR2820440550>3.0.CO;2-F

[5] Gaebe K, Erickson AW, Li AY, et al. Re-examining prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis[J]. EClinicalMedicine, 2024, 67: 102396. doi: 10.1016/j.eclinm.2023.102396

[6] Wu Q, Chen MY, Peng F, et al. A study of the prognosis of patients with limited-stage small cell lung cancer who did or did not receive prophylactic cranial irradiation after effective chemoradiotherapy[J]. Front Oncol, 2023, 13: 1118371. doi: 10.3389/fonc.2023.1118371

[7] Farooqi AS, Holliday EB, Allen PK, et al. Prophylactic cranial irradiation after definitive chemoradiotherapy for limited-stage small cell lung cancer: do all patients benefit?[J]. Radiother Oncol, 2017, 122(2): 307-312. doi: 10.1016/j.radonc.2016.11.012

[8] Xu JL, Yang HT, Fu XL, et al. Prophylactic cranial irradiation for patients with surgically resected small cell lung cancer[J]. J Thorac Oncol, 2017, 12(2): 347-353. doi: 10.1016/j.jtho.2016.09.133

[9] Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer[J]. N Engl J Med, 2007, 357(7): 664-672. doi: 10.1056/NEJMoa071780

[10] Steindl A, Yadavalli S, Gruber KA, et al. Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases[J]. Cancer, 2020, 126(19): 4341-4352. doi: 10.1002/cncr.33085

[11] Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2017, 18(5): 663-671. doi: 10.1016/S1470-2045(17)30230-9

[12] Liu SV, Reck M, Mansfield AS, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)[J]. J Clin Oncol, 2021, 39(6): 619-630. doi: 10.1200/JCO.20.01055

[13] Nadal E, Rodríguez-Abreu D, Simó M, et al. Phase Ⅱ trial of atezolizumab combined with carboplatin and pemetrexed for patients with advanced nonsquamous non-small-cell lung cancer with untreated brain metastases (Atezo-Brain, GECP17/05)[J]. J Clin Oncol, 2023, 41(28): 4478-4485. doi: 10.1200/JCO.22.02561

[14] Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC[J]. N Engl J Med, 2018, 379(24): 2342-2350. doi: 10.1056/NEJMoa1809697

[15] Paz-Ares L, Dvorkin M, Chen YB, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394(10212): 1929-1939. doi: 10.1016/S0140-6736(19)32222-6

[16] Lew A, Berghmans T, Andratschke N, et al. 174TiP PRIMALung (EORTC-1901): prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small cell lung cancer patients[J]. J Thorac Oncol, 2023, 18(4): S136. doi: 10.1016/S1556-0864(23)00428-8

[17] de Ruiter MB, Groot PFC, Deprez S, et al. Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small cell lung cancer reduces hippocampal atrophy compared to conventional PCI[J]. Neuro Oncol, 2023, 25(1): 167-176. doi: 10.1093/neuonc/noac148

[18] Grosshans DR, Meyers CA, Allen PK, et al. Neurocognitive function in patients with small cell lung cancer[J]. Cancer, 2008, 112(3): 589-595. doi: 10.1002/cncr.23222

[19] Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes[J]. Neurol Neuroimmunol Neuroinflamm, 2021, 8(4): e1014. doi: 10.1212/NXI.0000000000001014

[20] Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial[J]. Lancet Oncol, 2009, 10(5): 467-474. doi: 10.1016/S1470-2045(09)70101-9